Quantum Biopharma AI Stock Analysis
Want to see QNTM full AI Analyst Report?
Quantum Biopharma (QNTM) AI Stock Analysis
Quantum Biopharma
(NASDAQ:QNTM)
Overall score is driven primarily by weak financial performance (no revenue, ongoing losses, and negative cash flow) and a strongly bearish technical setup (price below all key moving averages with negative MACD). Low leverage is a partial stabilizer, but valuation support is limited because the company is loss-making and no dividend yield is available.
Quantum Biopharma (QNTM) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $10.35M
- Dividend Yield
- ―
- Average Volume (3M)
- 171.76K
- Price to Earnings (P/E)
- -0.4
- Beta (1Y)
- 1.00
- Revenue Growth
- ―
- EPS Growth
- 57.84%
- Country
- US
- Employees
- 17
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Quantum Biopharma Business Overview & Revenue Model
Company Description
Quantum BioPharma Ltd., a biopharmaceutical firm headquartered in Toronto, Canada, is dedicated to the discovery and advancement of biotechnological solutions and drug candidates. The company focuses on addressing complex neurodegenerative, inflammat...
Quantum Biopharma Financial Statement Overview
Summary
Financial profile is weak: zero revenue across periods with large, persistent losses (TTM net loss about $19.9M) and consistently negative operating/free cash flow (TTM OCF about -$6.4M). The key offset is low leverage (TTM debt-to-equity ~0.08) and modest absolute debt, which reduces near-term solvency risk, but ongoing losses continue to erode equity.
Income Statement
12Very NegativeBalance Sheet
43NeutralCash Flow
24Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -380.09K | 0 | 0 | 0 | 0 | 0 |
| EBITDA | -22.73M | -25.79M | -14.38M | -15.72M | -22.12M | -29.82M |
| Net Income | -19.87M | -26.18M | -14.20M | -17.90M | -23.61M | -35.29M |
Balance Sheet | ||||||
| Total Assets | 17.33M | 11.14M | 17.12M | 17.47M | 38.41M | 62.96M |
| Cash, Cash Equivalents and Short-Term Investments | 12.42M | 6.17M | 7.20M | 3.51M | 17.00M | 35.42M |
| Total Debt | 923.83K | 1.87M | 824.92K | 339.20K | 516.42K | 555.90K |
| Total Liabilities | 7.56M | 6.05M | 6.68M | 4.57M | 7.87M | 8.83M |
| Stockholders Equity | 11.80M | 6.91M | 11.48M | 13.24M | 30.54M | 54.13M |
Cash Flow | ||||||
| Free Cash Flow | -6.44M | -8.38M | -6.88M | -10.83M | -28.70M | -21.25M |
| Operating Cash Flow | -6.44M | -8.38M | -6.88M | -10.83M | -28.33M | -20.75M |
| Investing Cash Flow | -3.56M | -1.99M | -1.50M | -269.58K | 12.12M | 268.96K |
| Financing Cash Flow | 13.10M | 6.21M | 11.62M | -3.13M | -2.07M | 38.21M |
Quantum Biopharma Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For QNTM, the sentiment is Negative. The current price of 1.61 is below the 20-day moving average (MA) of 2.20, below the 50-day MA of 2.90, and below the 200-day MA of 3.68, indicating a bearish trend. The MACD of -0.29 indicates Positive momentum. The RSI at 22.10 is Positive, neither overbought nor oversold. The STOCH value of 5.44 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for QNTM.
Quantum Biopharma Risk Analysis
Quantum Biopharma disclosed 1 risk factors in its most recent earnings report. Quantum Biopharma reported the most risks in the "Legal & Regulatory" category.
Latest Risks Added
0 New RisksQuantum Biopharma Peers Comparison
Overall Rating
TSE:LABS57Neutral
TSE:ATLE42Neutral
TSE:AVCN42Neutral
TSE:INNO41Neutral- QNTM41Neutral
TSE:PCLO23Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| TSE:LABS | 57Neutral | CAD 27.77M | -10.00 | -7.66% | ― | -9.31% | 66.84% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| TSE:ATLE | 42Neutral | CAD 44.29M | -0.76 | -2099.75% | ― | -96.13% | 88.13% |
| TSE:AVCN | 42Neutral | CAD 13.44M | -4.54 | -65.40% | ― | -3.32% | -34.15% |
| TSE:INNO | 41Neutral | CAD 7.42M | -5.57 | -19.37% | ― | -19.20% | 42.54% |
| QNTM | 41Neutral | $13.02M | -0.38 | -291.59% | ― | ― | 57.84% |
| TSE:PCLO | 23Underperform | CAD 8.41M | -2.41 | 28.59% | ― | 0.90% | 57.73% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| QNTM | Quantum Biopharma Ltd. Subordinate Voting Shares Class B | 1.61 | -5.60 | -77.67% | |
| TSE:ATLE | Willow Biosciences | 0.10 | -0.08 | -44.12% | |
| TSE:LABS | Medipharm Labs (Otc) | 0.07 | -0.01 | -7.14% | |
| TSE:PCLO | Pharmacielo | 0.04 | 0.00 | 0.00% | |
| TSE:AVCN | Avicanna Inc | 0.10 | -0.13 | -55.56% | |
| TSE:INNO | Innocan Pharma Corporation | 1.65 | -14.05 | -89.49% |
Quantum Biopharma Corporate Events
Quantum BioPharma Reports Approximately 91% Equity Increase as Lucid-MS Phase 2 Study Start-Up Begins
Quantum BioPharma is a biopharmaceutical company developing assets and biotech solutions for neurodegenerative, metabolic and alcohol misuse disorders. For the quarter ended September 30, 2026, it reported approximately US$12.22 million in cash, cash...
Quantum Biopharma Reports Unaudited September 30 Interim Financials
Quantum Biopharma Ltd., formerly FSD Pharma Inc., reported unaudited interim financial statements for the three and nine months ended September 30, 2026, and comparative periods in 2025. The filing was dated November 12, 2026.As of September 30, 2026...
Quantum BioPharma Reports Shareholder Approvals and C$80.86 Private Placement
At its annual general and special meeting on November 10, 2026, Quantum BioPharma shareholders elected all five director nominees, reappointed MNP LLP as auditor and approved resolutions covering additional Class A Multiple Voting Shares, the 2026 om...
Quantum BioPharma Files Supplement Clarifying Proposed Share Consolidation
Quantum BioPharma is a biopharmaceutical company developing assets and biotech solutions for neurodegenerative and metabolic disorders and alcohol misuse disorders. Its portfolio includes Lucid-MS, a preclinical candidate targeting myelin degradation...
Quantum BioPharma Wins Consolidation of Market-Manipulation Lawsuits Against CIBC and RBC
On October 8, 2026, Quantum BioPharma Ltd. reported that the U.S. District Court for the Southern District of New York consolidated the company’s direct action with a class action brought by an individual investor alleging market manipulation of its...
Quantum BioPharma Taps Thermo Fisher to Launch Phase 2 Lucid-MS Trial
On October 6, 2026, Quantum BioPharma announced it had signed a Study Start-Up Agreement with Thermo Fisher Scientific’s clinical research business to implement a Phase 2 trial of its investigational multiple sclerosis therapy Lucid-MS. The deal brin...
Quantum BioPharma Highlights Year of Financing Moves, Debt Settlement and Governance Changes
In a series of announcements spanning March 2025 to August 2026, Quantum BioPharma undertook multiple capital markets and governance actions, including cancelling director Michael Zapolin’s 7,692 warrants on March 7, 2025 and replacing them with an e...
Quantum BioPharma Gains Rodman & Renshaw BUY Rating and US$8 Target
On September 17, 2026, Quantum BioPharma announced that investment bank Rodman & Renshaw has initiated equity research coverage on the company with a BUY rating and a US$8 price target. The unpaid coverage, led by Director of Research and Senior Biot...
Quantum BioPharma Showcases FDA-Backed Lucid-MS Program at Toronto Growth Summit
On September 15, 2026, Quantum BioPharma announced it will participate in the 3rd Annual ArcStone-Kingswood Growth Summit in Toronto, scheduled for September 16, 2026 at the Sheraton Centre Toronto Hotel. Co-founder and Executive Co-chairman Anthony...
Quantum BioPharma Boosts Liquidity as FDA Clears Pivotal Lucid-MS Phase 2 Trial
Quantum BioPharma reported second-quarter 2026 results on August 14, 2026 that show a markedly stronger balance sheet and improved liquidity. Cash, cash equivalents and digital assets rose to US$9.5 million as of June 30, 2026, nearly double year-end...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 14, 2026